Results 71 to 80 of about 106,721 (360)

Fine-mapping and molecular characterisation of primary sclerosing cholangitis genetic risk loci

Nature Communications
Genome-wide association studies of primary sclerosing cholangitis have identified 23 susceptibility loci. The majority of these loci reside in non-coding regions of the genome and are thought to exert their effect by perturbing the regulation of nearby ...
Elizabeth C. Goode, Laura Fachal, Nikolaos Panousis, Loukas Moutsianas, Rebecca E. McIntyre, Benjamin Yu Hang Bai, Norihito Kawasaki, Alexandra Wittmann, Tim Raine, Simon M. Rushbrook, Carl A. Anderson   +10 more
doaj   +1 more source

Clinical Features, Differential Diagnosis and Treatment of IgG₄-Related Sclerosing Cholangitis

Архивъ внутренней медицины
The aim: To present the state-of-the-art of clinical features, differential diagnosis and treatment of IgG4-related sclerosing cholangitis.Key points: IgG4-sclerosing cholangitis is a fibrotic inflammatory disease affecting the intrahepatic and ...
A. K. Guseva, A. V. Okhlobystin
doaj   +1 more source

A Gentleman with Anemia and Cholestasis

Case Reports in Medicine, 2010
Primary sclerosing cholangitis is a rare cause of cholestasis caused by progressive inflammation and fibrosis of both intrahepatic and extrahepatic bile ducts leading to multifocal ductal strictures.
Siu-Tong Law, Wai-Ki Lee, Michael Kin-Kong Li, Ka-Ho Lok   +3 more
doaj   +1 more source

Sump syndrome of the remnant common bile duct following a living donor liver transplant

Journal of Community Hospital Internal Medicine Perspectives, 2021
Sump syndrome – a collection of digested food, debris, stones, bile, and bacteria in a poorly drained, bile duct reservoir – occurs most commonly after a side-to-side choledochoduodenostomy.
Gordon Robbins, Justin Brilliant, Yuting Huang, Jonah Rubin, Eric Goldberg, Zurabi Lominadze   +5 more
doaj   +1 more source

Atezolizumab-induced Sclerosing Cholangitis in a patient with lung cancer: A case report

Cancer Treatment and Research Communications, 2021
Atezolizumab is an immune checkpoint inhibitor that is a key drug in non-small-cell lung cancer treatment. However, it can cause immune-related adverse events, including liver injury.
Shinji Nabeshima, Masahiro Yamasaki, Naoko Matsumoto, Shintaro Takaki, Yumi Nishi, Kazuma Kawamoto, Masaya Taniwaki, Nobuyuki Ohashi, Noboru Hattori   +8 more
doaj   +1 more source

Efficacy of hepatic transplantation in patients with primary sclerosing cholangitis [PDF]

, 1993
Controlled trials to assess the therapeutic benefit of orthotopic hepatic transplantation (OHTx) for primary sclerosing cholangitis (PSC) cannot be justified in view of improvement of patient survival after this operation since 1981.
Abu-Elmagd, KM, Demetris, AJ, Dickson, ER, Fung, JJ, Krom, RAF, Langworthy, AL, Malinchoc, M, Murtaugh, PA, Starzl, TE, Van Thiel, DH   +9 more
core  

Primary sclerosing cholangitis: a pre-malignant condition [PDF]

, 2017
Primary sclerosing cholangitis (PSC) is a chronic, progressive, cholestatic liver disease with no known cure. It is a serious condition, and diagnosis comes with an increased risk of developing cancer of the gallbladder, bile ducts or liver. Symptoms can
Mortimore, Gerri
core   +2 more sources

Serum Bile Acids Are Useful Indicators of Intrahepatic Recurrence After Initial Curative Hepatectomy for Hepatocellular Carcinoma

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Aim Bile acids accumulation in hepatocytes causes liver damage and contributes to the development of hepatocellular carcinoma. However, the association between serum bile acid levels and postoperative intrahepatic recurrence in hepatocellular carcinoma remains unclear.
Tomoaki Bekki, Masahiro Ohira, Yuki Imaoka, Seiichi Simizu, Tomoyuki Abe, Shintaro Kuroda, Hiroyuki Tahara, Kentaro Ide, Tsuyoshi Kobayashi, Hideki Ohdan   +9 more
wiley   +1 more source

Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies

Annals of Hepatology, 2020
Primary biliary cholangitis and primary sclerosing cholangitis are rare diseases affecting the bile ducts and the liver. The limited knowledge of their pathogenesis leads to limited therapeutic options.
Alessio Gerussi, Daphne D’Amato, Laura Cristoferi, Sarah Elizabeth O’Donnell, Marco Carbone, Pietro Invernizzi   +5 more
doaj   +1 more source

Pharmacological interventions for primary sclerosing cholangitis: an attempted network meta-analysis. [PDF]

, 2017
BACKGROUND: Primary sclerosing cholangitis is a chronic cholestatic liver disease that is associated with both hepatobiliary and colorectal malignancies, which can result in liver cirrhosis and its complications. The optimal pharmacological treatment for
Davidson, Brian R, Gurusamy, Kurinchi Selvan, Hawkins, Neil, Saffioti, Francesca, Thorburn, Douglas, Toon, Clare D, Tsochatzis, Emmanuel   +6 more
core   +4 more sources